‘Liquid gold' could bring new hope to multiple sclerosis patients, study suggests: ‘Profound benefit' [FOX News]
Clene Inc. (CLNN)
Company Research
Source: FOX News
Researchers may have hit "gold" when it comes to the treatment of multiple sclerosis An experimental medication called CNM-Au8 — a drinkable liquid with gold nanocrystals — has shown promising results in clinical trials in terms of improvements in MS symptoms. The "catalytically active" liquid, developed by Clene Nanomedicine in South Carolina , can cross the blood-brain barrier to help improve cellular energy and restore neurological function, according to researchers. Doctors at the University of Sydney presented the Phase 2 clinical trial findings at the American Academy of Neurology's annual meeting earlier in April 2024. The clinical trials included 78 patients who had relapsing multiple sclerosis. The gold liquid suspension was found to have a "profound clinical benefit," with the patients experiencing physical improvements not achieved in prior trials. Multiple sclerosis is an autoimmune disease of the central nervous system, brain, spinal cord and optic nerve. I
Show less
Read more
Impact Snapshot
Event Time:
CLNN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLNN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLNN alerts
High impacting Clene Inc. news events
Weekly update
A roundup of the hottest topics
CLNN
News
- NeuroSense taps PhaseV's ML tech for Phase III ALS trial analysis [Yahoo! Finance]Yahoo! Finance
- Clene to Present at Upcoming May Conferences [Yahoo! Finance]Yahoo! Finance
- Clene to Present at Upcoming May ConferencesGlobeNewswire
- Clene Inc. (NASDAQ: CLNN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights [Yahoo! Finance]Yahoo! Finance
CLNN
Earnings
- 5/8/24 - In-Line
CLNN
Sec Filings
- 5/8/24 - Form 4
- 5/8/24 - Form 8-K
- 5/8/24 - Form 10-Q
- CLNN's page on the SEC website